Organisation paid for research Program year 2025 Source: CMS Open Payments

Infinite Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$544,770

48 payments

Through program year 2025, Infinite Clinical Research Inc is reported as receiving $544,770 in research payments, across 48 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $65,082 3
2024 Research $70,259 3
2023 Research $215,383 8
2022 Research $47,439 8
2021 Research $101,737 10
2020 Research $38,893 15
2019 Research $5,979 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $339,404 11 payments
  2. Novartis Pharmaceuticals Corporation $54,898 4 payments
  3. Pfizer Inc. $54,628 2 payments
  4. Ge Healthcare $40,675 12 payments
  5. Chiesi USA, Inc. $26,294 4 payments
  6. Eisai Inc. $16,841 13 payments
  7. Amgen Inc. $12,030 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double-Blind Placebo-Controlled Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $169,233 1 payment
  2. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $132,452 4 payments
  3. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of An Oral Branchedchain Ketoacid Dehydrogenase Kinase Inhibitor Pf07328948 in Adults With Heart Failure Branchhf $54,628 2 payments
  4. A Phase 3 Open Label Multicenter Study of Flurpiridaz (18F) Injection for Positive Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease $36,498 8 payments
  5. A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging $26,444 1 payment
  6. A Study of Ly3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (Hfpef) $24,815 2 payments
  7. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $21,304 3 payments
  8. Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease $18,000 2 payments
  9. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $16,841 13 payments
  10. A Study of Ly3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (Hfpef) $12,873 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record